中山大便出鲜血有血块中山肛门流血但是不疼,中山哪个肛肠医院,中山便血但是不疼,中山大便时很费劲还拉出血来,中山痔疮手术多少天,中山上肠道出血,中山屁股痒是什么原因

SAN DIEGO (KGTV) — The community is coming together for the family of a San Diego mother of two who died this week while acting as a surrogate for another family.Michelle Reaves was helping a family have children of their own, according to a GoFundMe set up to help her family. It was her second surrogacy for the same family when complications arose and she died while giving birth, the campaign explained.The baby Reaves was carrying survived.Reaves leaves behind two children, Gage and Monroe, and her husband, Chris.The organizer of the GoFundMe campaign is hoping the community will "be there for Michelle’s family like they would for us.""I can’t even begin to imagine what her husband Chris and her two babies are going through so I want to start this page to help raise money for help with the kids, for Chris as they all adjust, funeral services, or anything at all to make it as easy as we can on them," wrote organizer Jaime Herwehe. "For those of you who didn’t have the pleasure of knowing Michelle, she will always be known for the love she had for her family. Michelle has the best, most sarcastic, funny personality and always had you laughing."You hear about these things happening all of the time but never in your life imagine it will happen to you." 1277

SAN DIEGO (KGTV) — The commissioner of the Pac-12 says 15-minute testing technology from a San Diego company could be the “game-changer” needed to restart competition in the conference before the end of the year.The Pac-12 is considering restarting college football as early as mid- to late-November, according to ESPN, as long as it can secure approvals from state and county lawmakers in California and Oregon.In some conferences, college football is entering its third week, but Pac-12 schools like USC and UCLA are still in workout mode after the conference voted last month to postpone all sports until 2021 at the earliest.League officials are now revisiting that decision and considering an earlier timeline after signing an agreement with San Diego-based Quidel Corporation to provide rapid antigen testing for all athletes, including daily tests for high-contact sports like football.“The access to rapid result testing that we can implement on even a daily basis with some sports with high contact will be a real game changer for us,” Pac-12 commissioner Larry Scott said after touring Quidel’s facility this month.Most nasal swab tests are genetic tests, or PCR tests, which seek out the genetic code buried inside the virus’ protein shell. These tests are considered the industry standard, but they require processing in a lab to convert RNA into enough readable strands of DNA. Results can sometimes take days.Quidel’s nasal swab test is what’s called an antigen test, which looks for parts of the virus’ protein shell. It can be read by machines at each university in about 15 minutes.“No one's going to be spreading the virus because no one will be engaging in practice or competition with the virus,” Scott said.That’s the hope at least, but the partnership with the Pac-12 will be an important test for Quidel’s diagnostic product.Quidel was the first company to get a rapid antigen test on the market, securing an emergency use authorization in May. But there were questions about the accuracy of the test compared to PCR tests in the small sample size provided by the company.In July, Quidel published more data showing its antigen tests matched up with PCR tests 96.7% of the time when a positive was detected. But those results were only among individuals who were actually showing symptoms.“The question that people have is in the asymptomatic population, will the data look similar?” said Quidel CEO Doug Bryant in an interview.Bryant said the company has unpublished data that will be forwarded to the FDA showing “very similar” relative accuracy to PCR tests in asymptomatic individuals, but he said the goal of the partnership with the Pac-12 is to investigate the tests even further.“We want to know that the tests we’re doing are appropriate for use in the asymptomatic population. And we need to demonstrate that, to not only the scientific community but to the public at large,” Bryant said.The testing program with the Pac-12 will essentially be a large clinical trial to find out if rapid testing of athletes can prevent spread, backed by the muscle at some of the premiere research universities.The Pac-12 is hoping the testing program will convince lawmakers to ease restrictions on college athletics, particularly in California.Although the NFL played a game at the new SoFI Stadium in Inglewood last weekend, nearby USC cannot gather in groups of more than 12 players.There are now four antigen tests on the market. Quidel plans to roll out its Sofia 2 testing machines to Pac-12 universities later this month. 3554

SAN DIEGO (KGTV) -- The FBI is asking for the public’s help identifying the man who reportedly robbed a San Diego bank. According to the agency, the man robbed a U.S. Bank located inside a Vons grocery store at 665 Saturn Boulevard. The suspect reportedly approached the teller and made a verbal demand for cash, telling the employee he had a gun. The man made off with an unspecified amount of cash. Pictures show the man wearing a hooded Padres sweatshirt and mirrored sunglasses. He is described as a white or possibly Middle Eastern man in his late 20s or early 30s. Anyone with information is asked to call the San Diego FBI at 858-320-1800 or Crime Stoppers at 888-580-8477. 689

SAN DIEGO (KGTV) — The downtown building at 101 Ash Street has been sitting vacant for most of the last four years and as it continues to sit empty, taxpayers are footing the ,000 per day bill.City Council leaders voted 5-4 — with Council members Vivian Moreno, Monica Montgomery, Barbara Bry, and Georgette Gómezto voting in opposition — to request monthly updates on the building's status and costs for several options presented by Mayor Kevin Faulconer's office.The mayor's options included putting millions of dollars more into the building for the needed repairs, buying out the lease, pursue a new landlord, trying to renegotiate its lease, or walking away entirely, the last of which could risk litigation and credit damage.The coronavirus pandemic has cleared out office buildings across downtown San Diego. But emptiness is business as usual for the old Sempra building at 101 Ash.In 2016, the city approved a lease-to-own agreement for the building, valued at million. The idea was to move upwards of 1,100 city employees into the facility.But officials quickly discovered a series of problems requiring major renovations to the site's 19 floors.In December 2019, the city finally began moving workers into the building, only to vacate them a month later when the county found traces of asbestos.So how did the city get into this mess? A new investigation shows it really never did its homework for such a big purchase from the start.The law firm Hugo Parker found that, "at no time, however, did the city formally inspect 101 Ash before closing escrow."In January, councilmember Barbara Bry showed ABC 10News a document that the city accepted the property as is."That is stupid to do when you are doing a long-term lease purchase on a building that was built in the 1960s," Bry said.An additional new report from Kitchell says the building needs 5 million of repairs, which is well more than what the city paid for it. 1947

SAN DIEGO (KGTV) — The National Institutes of Health highlighted research Tuesday out of UC San Diego that could unlock a new way to treat COVID-19.The research reveals new insight into how the coronavirus hijacks cells, and how doctors might be able to set traps or decoys to combat the virus. The findings were published in the journal Cell last month.“It does open up another avenue for a potential treatment,” said UC San Diego distinguished professor Dr. Jeffrey Esko. “It’s not a cure. It would be something that would tamp down infection potentially.”Since January, scientists around the world have understood that SARS-Co-V2, the official name of the new coronavirus, enters cells by latching onto a specific receptor on the cell’s surface, called ACE2.The UCSD team, led by Dr. Esko and visiting scholar Dr. Thomas Clausen, discovered that this entry mechanism is actually a two-step process, and the virus must also attach to a long chain of sugars called heparan sulfate.“We’ve shown this is fundamental to the infectious mechanism, so it needs to be part of every study from now on,” said Clausen.All cells are coated with a complex layer of sugars, or carbohydrates, called glycans. Heparan sulfate is one type of glycan that is known to play a key role in the infection process in several viruses, including herpes and other coronaviruses.It’s a complicated process to picture so the researchers offer an analogy: imagine a bird, soaring over trees, hunting a worm on the forest floor. The bird is the coronavirus and the trees are the thick layer of glycans that coat the surface of the cell.To reach the worm, which in this case is the receptor ACE2, the bird must navigate its way through the trees, specifically through heparan sulfate.The UCSD found that by removing the heparan sulfate trees with an enzyme, they were able to prevent the virus from infecting cells. In laboratory testing, they also found a second technique worked to foil the virus: introducing more trees as bait.The team found that heparin, an FDA-approved drug that is similar in structure to heparan sulfate, successfully acted as decoy. Heparin is a widely used drug designed to treat blood clots. Since blood clots and strokes are common complications with COVID-19, many doctors already administer heparin to patients.The UCSD team demonstrated that the two approaches can block infection in lab-grown cells about 80 to 90 percent of the time.“Certainly in the laboratory you can demonstrate that it works, but to deploy it and use it as a therapeutic has not been demonstrated,” Esko said.The NIH noted that more studies are planned to explore whether heparin, heparan sulfate, or drugs that target heparan sulfate might yield a viable COVID-19 treatment.Dr. Esko said he’s already been in talks with companies that plan to use their study as a rationale for a clinical trial.“It is very humbling when you realize we’re working on a pandemic right now, and maybe what we’ve done can contribute to a treatment for the disease,” he said. 3038